Three Infographics to Show You How to Overcome Challenges in Transitioning to Biologics Bioanalysis

Jul 8, 2016 | Biopharma, Blogs | 0 comments

The move to large molecules in Pharma is accelerating, offering unprecedented opportunities to improve human health and expand into new markets. But for those with extensive experience with small molecule bioanalysis, the shift to biologics can be challenging, from Sample Prep to Instrumentation and Software, to Methods and Training:

  • Sample Prep is complex
    • Every new biologic requires a specific sample prep strategy: sourcing reagents and researching protocols
    • Bioanalysis studies have large sample numbers
    • Tedious manual steps for enrichment, digestion, and clean-up can result in high variability
  • Instrumentation and Software have to be up to the task
    • Efficient MRM optimization is required for chromatography, multiple charge states, declustering potential and collision energy
    • Maximal sensitivity is needed for low abundance samples
    • Enhanced selectivity is important to overcome matrix interference
    • Simple software for complex data is essential, which can handle large sample sets and batches
  • Methods and Training are needed to get running quickly
    • You have to develop your sample prep protocol, source reagents and optimize your LC-MS methods, which can take months
    • You have to train your scientists to understand and run the new methods: how are you going to do it?

The challenges seem daunting, but SCIEX can help you overcome them with relative ease.  Download a three-part infographic that addresses all three challenges and describes the solutions with links to useful reference material.  The SCIEX BioBA Solution will get you up and running quickly and painlessly.Download Infographic >

Tips and tricks from our application experts: AAV analysis with CE

Peter Holper, Staff Applications Scientist at SCIEX, US, shares his tips and tricks on AAV analysis using CE with the BioPhase 8800 system and the PA 800 Plus system.

Pharma perspectives: The influence of LC-MS innovation on drug development outsourcing

It is no secret that (bio)pharmaceutical research and development is complex, both scientific and regulatory processes. Working for a contract research organization and more recently for SCIEX has provided an interesting perspective on trends the market experiences that affect many of us.

Overcoming uncertainty in your PFAS analysis

Just like gum on the bottom of a shoe, the existence of per- and poly-fluorinated alkyl substances (PFAS) in our environment is a sticky one. If you’re in the field of environmental testing, then you’re all too familiar with the threat these substances have on public health. While we have learned a lot about them over the years, there is still much more to understand. With the right detection methods, we can gather the information we need to empower us to make informed decisions on reducing the risks they impose.

Posted by

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial